Coley Fluid stimulates an immune response that can be
sufficiently powerful to induce the regression of cancer.
Dr. William Coley developed Coley Fluid in 1893. The
first immune therapy for cancer became a mainstream treatment manufactured
and distributed worldwide by several pharmaceutical companies. Coley Fluid
was responsible for numerous well-documented complete remissions of
advanced cancers that do not respond to modern therapies.
After Dr. Coley’s death in 1936, the use of Coley
Fluid and the number of commercial suppliers declined. In the United
Kingdom, the Lister Institute of Preventative Medicine ceased production
in 1943, and in the United States, Parke Davis & Company ceased production
in 1951. The German pharmaceutical company Südmedica ceased production in
1981 leaving no remaining commercial suppliers, and Coley Fluid was on the
brink of becoming a footnote to medical history.
MBVax Bioscience has developed an optimized version
of Coley Fluid and an administration protocol based on a modern
understanding of cancer immunology.
- 94% of patients have
benefited from therapy including improvement in pain, appetite,
depression, mobility, and/or regression of cancer.
- 70% of patients have
achieved confirmed regression of cancer.
- Twelve patients have
achieved complete remission (no detectable cancer).
Physicians have reported confirmed regressions in
17 different types of advanced cancer: breast, brain, cervical, colon,
esophageal, liver, lung, lymphoma, melanoma, multiple myeloma, ovarian,
pancreas, prostate, rectal, sarcoma, stomach and tongue. Complete
remissions (no remaining cancer) have been reported in two advanced
lymphomas, eight advanced breast cancers, and one each in advanced lung
cancer and stomach cancer.
MBVax Results for more complete information.